Role of adipose tissue and obesity in the development of reproductive disorders in women
O. V. Kosareva,
S. V. Bulgakova,
Yu. A. Dolgikh,
L. A. Sharonova,
E. V. Treneva,
D. P. Kurmaev,
P. Ya. Merzlova https://doi.org/10.31146/1682-8658-ecg-228-8-44-51
Abstract
In recent decades, obesity has been a pressing medical and social problem for all countries, including the Russian Federation. Obesity is an independent risk factor for the development of many chronic diseases, including reproductive and metabolic disorders. The article presents data on the prevalence of obesity among women. The effect of adipose tissue on reproductive function is shown - on ovarian function, on the endometrium, as well as on the activity of the hypothalamic-pituitary-ovarian system. The relationship between obesity and polycystic ovary syndrome, infertility, and metabolic menopausal syndrome is discussed. The mechanisms of the impact of obesity on the pathogenesis of reproductive disorders in women are considered.
About the Authors
O. V. Kosareva
Samara State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
S. V. Bulgakova
Samara State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Yu. A. Dolgikh
Samara State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
L. A. Sharonova
Samara State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
E. V. Treneva
Samara State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
D. P. Kurmaev
Samara State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
P. Ya. Merzlova
Samara State Medical University of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. WHO (2020), Obesity and overweight, URL: https://www.who.int/news-room/factsheets/detail/obesity-and-overweight.
2. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016 Apr 2;387(10026):1377-1396. doi: 10.1016/S0140-6736(16)30054-X.
3. Balanova Yu.A., Shalnova S. A., Deev A. D. et al. Obesity in russian population - prevalence and association with the non-communicable diseases risk factors.Russian Journal of Cardiology. 2018;(6):123-130. (In Russ.) doi: 10.15829/1560-4071-2018-6-123-130.@@ Баланова Ю. А., Шальнова С. А., Деев А. Д. и др. Ожирение в российской популяции - распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2018;(6):123-130. doi: 10.15829/1560-4071-2018-6-123-130.
4. Mendes K. G., Theodoro H., Rodrigues A. D., Olinto M. T. Prevalência de síndrome metabólica e seus componentes na transição menopáusica: uma revisão sistemática [Prevalence of metabolic syndrome and its components in the menopausal transition: a systematic review]. Cad Saude Publica. 2012;28(8):1423-1437. doi: 10.1590/s0102-311x2012000800002.
5. World Health Organization. Noncommunicable Diseases Country Profiles 2018.Russian Federation. (in Russ.) Available at: https://www.who.int/nmh/countries/2018/rus_en.pdf?ua=1.
6. Dedov I. I., Shestakova M. V., Melnichenko G. A., et al.Interdisciplinary clinical practice guidelines “Management of obesity and its comorbidities”. Obesity and metabolism. 2021;18(1):5-99. (In Russ.) doi: 10.14341/omet12714.@@ Дедов И. И., Шестакова М. В., Мельниченко Г. А. и др. Междисциплинарные клинические рекомендации «Лечение ожирения и коморбидных заболеваний». Ожирение и метаболизм. 2021;18(1):5-99. doi: 10.14341/omet12714.
7. Lenz M., Arts I. C.W., Peeters R. L.M. et al. Adipose tissue in health and disease through the lens of its building blocks. Sci Rep. 2020;10(1):10433. doi: 10.1038/s41598-020-67177-1.
8. Romantsova T. I. Adipose tissue: colors, depots and functions. Obesity and metabolism. 2021;18(3):282-301. (In Russ.) doi: 10.14341/omet12748.@@ Романцова Т. И. Жировая ткань: цвета, депо и функции. Ожирение и метаболизм. 2021;18(3):282-301. doi: 10.14341/omet12748.
9. Jungheim E. S., Travieso J. L., Hopeman M. M. Weighing the impact of obesity on female reproductive function and fertility. Nutr Rev. 2013;71 Suppl 1(0 1): S3-S8. doi: 10.1111/nure.12056.
10. Tkachenko L. V., Andreyeva M. V., Sviridova N. I. et al. Obesity and the reproductive function: the current state of the problem. Vopr. ginekol. akus. perinatol. Gynecology, Obstetrics and Perinatology. 2019;18(3):106-113. (In Russ.) doi: 10.20953/1726-1678-2019-3-106-113.@@ Ткаченко Л. В., Андреева М. В., Свиридова Н. И. и др. Ожирение и репродуктивная функция: современное состояния проблемы. Вопросы гинекологии, акушерства и перинатологии. 2019;18(3):106-113. doi: 10.20953/1726-1678-2019-3-106-113.
11. Ogbuji Q. C. Obesity and reproductive performance in women. Afr J Reprod Health. 2010;14(3):143-151.
12. Abdusalamova A. I., Bettikher O. A., Rudenko K. A. et al. Adipokinesand Ghrelin Rolein Regulation of Ovarian Function in Obesity. Obesity and metabolism. 2022;19(3):324-331. (In Russ.) doi: 10.14341/omet12825.@@ Абдусаламова А. И., Беттихер О. А., Руденко К. А. и др. Роль адипокинов и грелина в регуляции овариальной функции при ожирении. Ожирение и метаболизм. 2022;19(3):324-331. doi: 10.14341/omet12825.
13. Sharma A., Bahadursingh S., Ramsewak S., Teelucksingh S. Medical and surgical interventions to improve outcomes in obese women planning for pregnancy. Best Pract Res Clin Obstet Gynaecol. 2015;29(4):565-576. doi: 10.1016/j.bpobgyn.2014.12.003.
14. Michalakis K., Mintziori G., Kaprara A. et al. The complex interaction between obesity, metabolic syndrome and reproductive axis: a narrative review. Metabolism. 2013;62(4):457-478. doi: 10.1016/j.metabol.2012.08.012.
15. Nikolettos K., Vlahos N., Pagonopoulou O. et al. The association between leptin, adiponectin levels and the ovarian reserve in women of reproductive age. Front Endocrinol (Lausanne). 2024;15:1369248. doi: 10.3389/fendo.2024.1369248.
16. Vedzizheva E. R., Kuznetsova I. V., Uspenskaya Yu.B. et al. On the pathogenesis of reproductive disorders in women with obesity. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017;6:18-24. (in Russ.) doi: 10.18565/aig.2017.6.18-24.@@ Ведзижева Э. Р., Кузнецова И. В., Успенская Ю. Б. и др. К вопросу о патогенезе репродуктивных нарушений у женщин с ожирением. Акушерство и гинекология. 2017;6:18-24. doi: 10.18565/aig.2017.6.18-24.
17. Shpakov A. O. Visfatin and Its Role in the Regulation of the Reproductive System. Translational Medicine. 2019;6(2):25-36. (In Russ.) doi: 10.18705/2311-4495-2019-6-2-25-36.@@ Шпаков А. О. Висфатин и его роль в регуляции репродуктивной системы. Трансляционная медицина. 2019;6(2):25-36. doi: 10.18705/2311-4495-2019-6-2-25-36.
18. Gul O. O., Cander S., Gul B. et al. Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome. Eur Cytokine Netw. 2015;26(4):73-78. doi: 10.1684/ecn.2015.0370.
19. Diot M., Reverchon M., Ramé C. et al. Expression and effect of NAMPT (visfatin) on progesterone secretion in hen granulosa cells. Reproduction. 2015;150(1):53-63. doi: 10.1530/REP-15-0021.
20. Reverchon M., Rame C., Bunel A. et al. VISFATIN (NAMPT) Improves In Vitro IGF1-Induced Steroidogenesis and IGF1 Receptor Signaling Through SIRT1 in Bovine Granulosa Cells. Biol Reprod. 2016;94(3):54. doi: 10.1095/biolreprod.115.134650.
21. Maillard V., Elis S., Desmarchais A. et al. Visfatin and resistin in gonadotroph cells: expression, regulation of LH secretion and signalling pathways. Reprod Fertil Dev. 2017;29(12):2479-2495. doi: 10.1071/RD16301.
22. Tsouma I., Kouskouni E., Demeridou S. et al. Correlation of visfatin levels and lipoprotein lipid profiles in women with polycystic ovary syndrome undergoing ovarian stimulation. Gynecol Endocrinol. 2014;30(7):516-519. doi: 10.3109/09513590.2014.896896.
23. Spanos N., Tziomalos K., Macut D. et al. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss. Obes Facts. 2012;5(4):495-504. doi: 10.1159/000341579.
24. Nejabati H. R., Samadi N., Shahnazi V. et al. Nicotinamide and its metabolite N1-Methylnicotinamide alleviate endocrine and metabolic abnormalities in adipose and ovarian tissues in rat model of Polycystic Ovary Syndrome. Chem Biol Interact. 2020;324:109093. doi: 10.1016/j.cbi.2020.109093.
25. Annie L., Gurusubramanian G., Roy V. K. Inhibition of visfatin by FK866 mitigates pathogenesis of cystic ovary in letrozole-induced hyperandrogenised mice. Life Sci. 2021;276:119409. doi: 10.1016/j.lfs.2021.119409.
26. Chen P., Jia R., Liu Y. et al. Progress of Adipokines in the Female Reproductive System: A Focus on Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2022;13: 881684. doi: 10.3389/fendo.2022.881684.
27. Khoshi A., Bajestani M. K., Shakeri H. et al. Association of Omentin rs2274907 and FTO rs9939609 gene polymorphisms with insulin resistance in Iranian individuals with newly diagnosed type 2 diabetes. Lipids Health Dis. 2019;18(1):142. doi: 10.1186/s12944-019-1085-5.
28. Franik G., Sadlocha M., Madej P. et al. Circulating omentin-1 levels and inflammation in polycystic ovary syndrome. Ginekol Pol. 2020;91(6):308-312. doi: 10.5603/GP.2020.0057.
29. Tang Y. L., Yu J., Zeng Z. G. et al. Circulating omentin-1 levels in women with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol. 2017;33(3):244-249. doi: 10.1080/09513590.2016.1254180.
30. Yang H. Y., Ma Y., Lu X. H. et al. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome. Ann Endocrinol (Paris). 2015;76(5):620-627. doi: 10.1016/j.ando.2015.08.002.
31. Choi J. H., Rhee E. J., Kim K. H. et al. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol. 2011;165(5):789-796. doi: 10.1530/EJE-11-0375.
32. Kenawi M. Z., Akl E. M., Sabry J. H., Mostafa S. T. Evaluation of serum level of omentin-1 in females with hirsutism. J Cosmet Dermatol. 2020;19(2):535-539. doi: 10.1111/jocd.13043.
33. Pandey G. K., Balasubramanyam J., Balakumar M. et al. Altered circulating levels of retinol binding protein 4 and transthyretin in relation to insulin resistance, obesity, and glucose intolerance in asian indians. Endocr. Pract. 2015;21(8):861-869. doi: 10.4158/EP14558.OR.
34. Jaberi S. A., Cohen A., D’Souza C. et al. Lipocalin-2: Structure, function, distribution and role in metabolic disorders. Biomed Pharmacother. 2021;142:112002. doi: 10.1016/j.biopha.2021.112002.
35. Wang Y., Lam K. S., Kraegen E. W. et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem. 2007;53(1):34-41. doi: 10.1373/clinchem.2006.075614.
36. Zhang S. L., Li Z. Y., Wang D. S. et al. Aggravated ulcerative colitis caused by intestinal Metrnl deficiency is associated with reduced autophagy in epithelial cells. Acta Pharmacol Sin. 2020;41(6):763-770. doi: 10.1038/s41401-019-0343-4.
37. Rupérez C., Ferrer-Curriu G., Cervera-Barea A. et al. Meteorin-like/Meteorin-β protects heart against cardiac dysfunction. J Exp Med. 2021;218(5): e20201206. doi: 10.1084/jem.20201206.
38. Deniz R., Yavuzkir S., Ugur K. et al. Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome. J Obstet Gynaecol. 2021;41(2):279-284. doi: 10.1080/01443615.2020.1758926.
39. Fouani F. Z., Fadaei R., Moradi N. et al. Circulating levels of Meteorin-like protein in polycystic ovary syndrome: A case-control study. PLoS One. 2020;15(4): e0231943. doi: 10.1371/journal.pone.0231943.
40. Zhou X., Chen Y., Tao Y. et al. Serum Vaspin as a Predictor of Adverse Cardiac Events in Acute Myocardial Infarction. J Am Heart Assoc. 2019;8(2): e010934. doi: 10.1161/JAHA.118.010934.
41. Mehrabani S., Arab A., Karimi E. et al. Blood Circulating Levels of Adipokines in Polycystic Ovary Syndrome Patients: A Systematic Review and Meta-analysis. Reprod Sci. 2021;28(11):3032-3050. doi: 10.1007/s43032-021-00709-w.
42. Dogan K., Helvacioglu C., Baghaki S, Ekin M.Comparison of body mass index and metabolic parameters with serum vaspin levels in women with polycystic ovary syndrome. Diabetes Metab Syndr. 2020;14(2):137-139. doi: 10.1016/j.dsx.2020.01.008.
43. Koiou E., Dinas K., Tziomalos K. et al. The phenotypes of polycystic ovary syndrome defined by the 1990 diagnostic criteria are associated with higher serum vaspin levels than the phenotypes introduced by the 2003 criteria. Obes Facts. 2011;4(2):145-150. doi: 10.1159/000327935.
44. Tan B. K., Chen J., Farhatullah S. et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes. 2009;58(9):1971-1977. doi: 10.2337/db08-1528.
45. Li X., Zhu Q., Wang W. et al. Elevated chemerin induces insulin resistance in human granulosa-lutein cells from polycystic ovary syndrome patients. FASEB J. 2019;33(10):11303-11313. doi: 10.1096/fj.201802829R.
46. Estienne A., Mellouk N., Bongrani A. et al. Involvement of chemerin and CMKLR1 in the progesterone decrease by PCOS granulosa cells. Reproduction. 2021;162(6):427-436. doi: 10.1530/REP-21-0265.
47. Petrov Yu.A., Palieva N. V., Allakhyarov D. Z. Pathogenetic aspects of reproductive health disorders in obese women. Modern Problems of Science and Education. Surgery. 2022;1:102. (In Russ.) doi: 10.17513/spno.31486.@@ Петров Ю. А., Палиева Н. В., Аллахяров Д. З. Патогенетические аспекты нарушения репродуктивного здоровья у женщин с ожирением. Современные проблемы науки и образования. 2022;1:102. doi: 10.17513/spno.31486.
48. Shilova O. Yu., Gladkaya V.S Insulin resistance and reproductive damage (literature review). Mother and Baby in Kuzbass. 2018;4:13-20. (In Russ.)@@ Шилова О. Ю., Гладкая В. С. Инсулинорезистентность и нарушение репродукции (обзор литературы). Мать и дитя в Кузбассе. 2018;4:13-20.
49. Radynova S.B., Kenyakina A. G., Turaeva M. A., Lodyreva M. S. The effect of metabolic syndrome on women’s reproductive function. Colloquium-journal. 2019;4(28):9-11. (In Russ.)@@ Радынова С. Б., Кеняйкина А. Г., Тураева М. А., Лодырева М. С. Влияние метаболического синдрома на репродуктивную функцию женщин. Colloquium-journal. 2019;4(28):9-11.
50. Kishkina A. Yu., Kolomiets L. A., Yunusova N. V. Structural features of the metabolic syndrome: clinical and epidemiological aspects. Relationship with proliferative processes and endometrial cancer. Voprosy onkologii. 2019,65(4):488-497. (In Russ.) doi: 10.37469/0507-3758-2019-65-4-488-497.@@ Кишкина А. Ю., Коломиец Л. А., Юнусова Н. В. Структурные особенности метаболического синдрома: клинико-эпидемиологические аспекты. Взаимосвяь с пролиферативными процессами и раком эндометрия. Вопросы онкологии. 2019,65(4):488-497. doi: 10.37469/0507-3758-2019-65-4-488-497.
51. Gorbatenko N. V., Bezhenar V. F., Fishman M. B. Obesity and reproductive health of women (analytical literature review). Obesity and metabolism. 2017;14(1):3-8. (In Russ.) doi: 10.14341/omet201713-8.@@ Горбатенко Н. В., Беженарь В. Ф., Фишман М. Б. Влияние ожирения на развитие нарушения репродуктивной функции у женщин (аналитический обзор литературы). Ожирение и метаболизм. 2017;14(1):3-8. doi: 10.14341/OMET201713-8.
52. Goodman N. F., Cobin R. H., Futterweit W. et al. American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androge Excess and PCOS Society. American association of clinical endocrinologists, american college of endocrinology, and androgen excess and pcos society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2. Endocr Pract. 2015;21(12):1415-1426. doi: 10.4158/EP15748.DSCPT2.
53. Durmanova A. K., Otarbaev N. K. Anti-Muller hormone as an indicator of reproductive health of women with obesity and concomitant polycystic ovary syndrome. Therapeutic archive. 2016;88(12):41-44. (In Russ.) doi: 10.17116/terarkh2016881241-44.@@ Дурманова А. К., Отарбаев Н. К. Антимюллеров гормон как показатель репродуктивного здоровья женщин с ожирением и сопутствующим синдромом поликистозных яичников. Терапевтический архив. 2016;88(12):41-44. doi: 10.17116/terarkh2016881241-44.
54. Bolotova E. V., Dudnikova A. V., Krutova V. A., Prosolupova N. S. The frequency and structure of metabolic disorders in obese women in combination with polycystic ovary syndrome. Obesity and metabolism. 2021;18(3):254-262. (In Russ.) doi: 10.14341/omet12374@@ Болотова Е. В., Дудникова А. В., Крутова В. А., Просолупова Н. С. Частота и структура метаболических нарушений у женщин с ожирением в сочетании с синдромом поликистозных яичников. Ожирение и метаболизм. 2021;18(3):254-262. doi: 10.14341/omet12374.
55. Zhuk T. V., Yavorskaya S. D., Vostrikov V. V. Obesity, reproduction and oxidative stress. Obesity and metabolism. 2017;14(4):16-22. (In Russ.) doi: 10.14341/omet2017416-22.@@ Жук Т. В., Яворская С. Д., Востриков В. В. Ожирение, репродукция и оксидативный стресс. Ожирение и метаболизм. 2017;14(4):16-22. doi: 10.14341/omet2017416-22.
Review
For citations:
Kosareva O.V., Bulgakova S.V., Dolgikh Yu.A., Sharonova L.A., Treneva E.V., Kurmaev D.P., Merzlova P.Ya. Role of adipose tissue and obesity in the development of reproductive disorders in women. Experimental and Clinical Gastroenterology. 2024;(8):44-51. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-228-8-44-51
Views:
260
Email this article 